Filing Flows › Health Care › Orthofix Medical (OFIX)
Orthofix Medical (OFIX) earnings and revenue breakdown
Latest: Q2 FY26 · 10-Q filed Aug 5, 2026 · Orthofix Medical (OFIX) Q2 FY26 earnings results →
Q2 FY26 Revenue up 4% year over year to $211M · 7¢ of every $1 of revenue lost · operating margin -3.9%
Orthofix Medical made $211M in Q2 FY26 (+4% Y/Y): Global Spine $173M, Global Limb Reconstruction $37.7M. Operating margin -3.9%, net loss $15.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $210.9M in Q2 FY26, up 4% year over year and up 7% from the previous quarter. Global Spine was the largest line at 82% of revenue. Global Limb Reconstruction added $4.4M year over year (up 13%), 56% of the total change.
Gross margin was 71.0%, up 2.3 points from Q2 FY25. Operating costs exceeded revenue by $8.1M, an operating margin of -3.9%. Operating expenses grew 1% against revenue growth of 4%. The fastest-growing cost line was Other operating costs (+24%). The quarter ended with a net loss of $15.8M, narrower than the previous quarter's $20.9M loss.
Operating cash flow was −$6.2M. Non-cash charges added back $13.3M of depreciation and amortization and $7.7M of share-based compensation. Working capital and other items used $11.4M. Capital expenditures of $12.6M exceeded it, leaving free cash flow of −$18.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 FY26 | 10-Q | Aug 5, 2026 | $211M | +4% | -3.9% | −$15.8M | −$6.2M |
| Q1 FY26 | 10-Q | May 5, 2026 | $197M | +2% | -7.3% | −$20.9M | −$17.6M |
| Q4 FY25 | 10-K | Feb 24, 2026 | $220M | +2% | 0.2% | −$2.2M | $27.7M |
| Q3 FY25 | 10-Q | Nov 4, 2025 | $206M | +5% | -8.3% | −$22.8M | $12.4M |
| Q2 FY25 | 10-Q | Aug 5, 2025 | $203M | +2% | -7.9% | −$14.1M | $11.6M |
| Q1 FY25 | 10-Q | May 6, 2025 | $194M | +3% | -25.2% | −$53.1M | −$18.4M |
| Q4 FY24 | 10-K | Feb 25, 2025 | $216M | +8% | -5.3% | −$29.1M | $23.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Orthofix Medical
Orthofix is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company offers a differentiated portfolio of spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH™ Navigation System. Orthofix’s technology-enabled solutions are designed to support surgeons across the continuum of care and improve outcomes for patients. Learn more at Orthofix.com and follow Orthofix on LinkedIn .
In its own words, from its 8-K, filed Aug 5, 2026.
Orthofix Medical against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +4% against the peers' median +5%. Operating margin: -3.9% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OFIX Orthofix Medical | Q2 FY26 | $211M | +4% | -3.9% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Orthofix Medical 10-Q on SEC EDGAR · CIK 884624 · Surgical & Medical Instruments & Apparatus
13F: who owns OFIX and who is buying
More on OFIX
History
Every quarter: Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q1 FY25 results · Q4 FY24 results